LUMC received large EU subsidy for stem cell correction of babies without immune systemSeptember 20, 2017
Project kick-off meetingApril 10, 2018
On January 1st, 2018 the RECOMB project has started. The aim of the project is to fill the unmet medical need for the most common major category of SCID, recombination activating gene-1 (RAG-1) deficient SCID, by performing Stage I/II clinical trials using autologous hematopoietic stem cell basedgene therapy. The RECOMB consortium, with 17 partner institutes, brings together a large number of clinical and research experts in the field of management of a lethal orphan disease, i.e., SCID to provide solutionfor the treatment of SCID patients. Read more about our project and consortium.